艾曲泊帕联合环孢素治疗难治性免疫性血小板减少症的效果观察  

Effect of eltrombopag combined with cyclosporin in treatment of patients with refractory immune thrombocytopenia

作　　者：周茉[1] 邵钰[1] 单学赟[1] 王品 孙乃同[1] ZHOU Mo;SHAO Yu;SHAN Xueyun;WANG Pin;SUN Naitong(Department of Hematology,Yancheng City Third People′s Hospital of Jiangsu Province,Yancheng Clinical Medical College of Nanjing Medical University,the Sixth Affiliated Hospital of Nantong University,Yancheng,Jiangsu,224000)

机构地区：[1]江苏省盐城市第三人民医院/南京医科大学盐城临床医学院/南通大学第六附属医院血液科,江苏盐城224000

出　　处：《实用临床医药杂志》2022年第10期51-53,共3页Journal of Clinical Medicine in Practice

基　　金：江苏省盐城市医学科技发展计划项目(YK2013067)。

摘　　要：目的探讨艾曲泊帕联合环孢素用于难治性免疫性血小板减少症(ITP)的疗效及安全性。方法根据治疗方案的不同,将39例难治性ITP患者分为试验组16例(接受艾曲泊帕联合环孢素治疗)和对照组23例(使用环孢素治疗)。记录治疗前、治疗3个月及9个月后患者血小板计数情况,评价药物不良反应和疗效。结果治疗3个月后,对照组总有效率为69.57%,试验组为81.25%,差异无统计学意义(P>0.05);治疗9个月后,对照组总有效率为34.78%,试验组总有效率为62.50%,差异有统计学意义(P<0.05);试验组不良反应总发生率为37.50%(6/16),对照组不良反应总发生率为39.13%(9/23),差异无统计学意义(P>0.05)。结论艾曲泊帕联合环孢素能够提高难治性ITP患者的血小板计数,改善临床症状,安全性较高,治疗依从性高。Objective To explore the efficacy and safety of eltrombopag combined with cyclosporin in the treatment of patients with refractory immune thrombocytopenia(ITP).Methods According to the different therapeutic plans,a total of 39 patients with refractory ITP were divided into experimental group with 16 cases(treated with eltrombopag and cyclosporin)and control group with 23 cases(treated with cyclosporin).Platelet count of patients before treatment and 3,9 months after treatment were recorded,therapeutic effect and effective rate were evaluated,and the adverse reactions of drugs and efficacy during treatment were observed and followed up.Results After 3 months of treatment,the total effective rate of the control group and the experimental group was 69.57%and 81.25%respectively,and there was no significant difference between two groups(P>0.05).After 9 months of treatment,the total effective rate of the control group and the experimental group was 34.78%and 62.50%respectively,and there was a significant difference between the two groups(P<0.05).The total incidence of adverse reactions in the experimental group and the control group was 37.50%(6/16)and 39.13%(9/23)respectively,and there was no significant difference between two groups(P>0.05).Conclusion Eltrombopag combined with cyclosporine can increase the platelet count of patients with refractory ITP and improve the clinical symptoms,and has higher safety and compliance.

关 键 词：艾曲泊帕 环孢素 免疫性血小板减少症 肝功能 

分 类 号：R979.5[医药卫生—药品] R558.2[医药卫生—药学]